Publications
Publications
- Therapeutic Targeting of Vasculature in the Premetastatic and MetastaticNiches Reduces Lung Metastasis. Ghouse SM, Vadrevu SK, Manne S, Reese B, Patel J, Patel B, Silwal A, Lodhi N, Paterson Y, Srivastava SK, Karbowniczek M, Markiewski MM. J Immunol. 2020 Jan 3. poo: jil901208. doj: 10.4049/jimmunol. 1901208 [Epub ahead of print]
- Optimizing Patient Outcomes with PD-1L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer. La-Beck NM, Nguyen DT, Le AD, Alzghari SK, Trinh ST. Pharmacotherapy. 2020 Jan 12. doi: 10.1022/phar.2364. [Epub ahead of print]
- Oxidative Stress and Cancer: Chemopreventive and Therapeutic Role of Triphala. Prasad S, Srivastava SK, Antioxidants (Basel). 2020 Jan 13:9(1). pii: E72. doi: 10.3390/antiox9010072. Review
- The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch-Nodal Axis. Cho JH, Patel B, Bonala S, Mansouri H, Manne S, Vadrevu SK, Ghouse S, Kung CP, Murphy ME, Astrinidis A, Henske, Kwiatkowski DJ, Markiewski MM, Karbowniczek M. Mol Cancer Res. 2019 Aug: 17(8): 1639-1651. doi: 10.1158/1541-7786. MCR-18-1292. Epub 2019 May 14.
- Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Clinical Guidlines. Trinh S, Gowani S. La-Beck NM Asia Pac J Oncol Nurs. 2019 Apr-Jun:6(2): 154-160. doi: 10.4103/apjon_3_19. Review.
- Harnessing Liposome Interactions with the Immune System for the Next Breakthrough in Cancer Drug Delivery. La-Beck NM, Lui X, Wood LM. Front Pharmacol. 2019 Mar 12:10:220. doi: 10.3389/fphar.2019.00220. eCollection 2019.
- Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. La-Beck NM, Lui X, Shmeeda H, Shudde C, Gabizon AA. Semin Cancer Biol. 2019 Dec 23. pii: S1044-579X(19) 30396-7. doi: 10.1016/j.semcancer. 2019.12.001.
- Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D. J Biol Methods. 2019:6(2). Epub 2019 Apr 4. PubMed PMID: 31123687; PubMed Central PMCID: PMC6528664
- Expression and characterization of soluble epitope-defined major histocompatibility complex (MHC) from stable eukaryotic cell lines. Wooster AL, Anderson TS, Lowe DB. J Immunol Methods. 2019 Jan464:22-30. doi: 10.1016/j.jim.2018.10.006. Epub 2018 Oct 19. PubMed PMID: 30347189; PubMed Central PMCID: PMC6322931
- Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy. Saha D, Rabkin SD. Methods Mol Biol.2020:2058:179-190. doi: 10.1007/978-1-4939-9794-7_11.
- Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy. Shaw V, Srivastava S. Srivastava SK. Semin Cancer Biol. 2019 Oct 13. pii: S1044-579X(19)30144-0. doi: 10.1016/j.semcancer.2019.10.007
- Role of Phytochemicals in Caner Prevention. Ranjan A, Ramachandran S, Gupta N, Kaushik I, Wright S, Srivastava S, Das H, Prasad, Srivastava SK. Int J Mol Cancer Ther. 2019 Oct: 18(10).1158/1535-7163. MCT-18-1286. Epub 2019 Jul 3.
- Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/B-Catenin Signaling. Gupta N, Srivastava SK. Mol Cancer Ther. 2019 Oct. 18(10):1708-1720. doi 10.1158/1535-7163.MCT-18-1286. Epub 2019 Jul 3.
- CRISPR-Cas9: Amultifaceted therapuetic strategry for cancer treatment. Kaushik I, Ramachandran S, Srivastava SK. Semin Cell Dev Biol. 2019 Dec:96:4-12. doi: 10.1016/j.semcdb.2019 May 4. Review
- Penfluridol overcomes paclitaxel resistance in metastatic breast cancer. Kaushik I, Ramachandran S, Srivastava SK. Sci Rep. 2019 Mar 25:9(1):5066. doi: 10.1038/s41598-019-41632-0.
- Cancer cells stemness: A doorstep to targeted therapy. Prasad S. Ramachandran S, Gupta N, Fofaria NM, Ranjan A, Srivastava SK.
- HER2-mediated GLI2 stabilization promotes anoikis resistance and metastatis of breast cancer cells. Gupta P, Gupta N, Fofaria NM, Ranjan A, Srivastava Sk
- Mutations in cancer driver genes: an insight into prostate cancer progression. Annals of Urologic Oncology. Prasad S and Srivastava SK.
- Kochanek DM, Ghouse SM, Karbowniczek MM*, Markiewski MM*. Complementing Cancer Metastasis.
Front Immunol. 2018 Jul 16;9:1629. doi: 10.3389/fimmu.2018.01629. eCollection 2018.
Review. PubMed PMID: 30061895; PubMed Central PMCID: PMC6054933.
Co-corresponding authors
Impact Factor of 6.429 - Kolev M, Markiewski MM. Targeting complement-mediated immunoregulation for cancer
immunotherapy. Seminars in immunology. 2018; 37:85-97. NIHMSID: NIHMS943398 PubMed
[journal] PMID: 29454575, PMCID: PMC5984681,
Impact factor: 7.206
- La-Beck NM, Gabizon AA. Nanoparticle interactions with the immune system: clinical implications for liposome-based cancer chemotherapy. Frontiers Immunology 2017;8:416. ^Co-corresponding author
- Le A, Alzghari, S, Jean G, La-Beck NM*. Update on targeted therapies for advanced non-small cell lung cancer - nivolumab in context. Therapeutics and Clinical Risk Management 2017;13:223-236. *Corresponding author
- Walko CM, Aubert RE, La-Beck NM, Clore G, Herrera V, Kourlas H, Epstein RS, McLeod HL. Pharmacoepidemiology of clinically-relevant hypothyroidism and hypertension from sunitinib and sorafenib. The Oncologist 2017;22:208-212.
- Anchordoquy TJ, Barenholz Y, [and 18 others, including La-Beck NM]. Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano 2017;11(1):12-18.
- Lowe DB, Bivens CK, Mobley AS, Herrera CE, McCormick AL, Wichner T, Sabnani MK, Wood LM, Weidanz JA. TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets. MAbs. 2017 May/Jun;9(4):603-614. doi: 10.1080/19420862.2017.1302630.
- Kim CG, Lee H, Gupta N, Ramachandran S, Kaushik I, Srivastava S, Kim SH, Srivastava
SK. Role of Forkhead Box Class O proteins in cancer progression and metastasis. Semin
Cancer Biol. 2017 Aug 1. pii: S1044-579X(17)30092-5. doi: 10.1016/j.semcancer.2017.07.007.
[Epub ahead of print] Review.
PMID: 28774834 - Ranjan A and Srivastava SK (2017). Penfluridol suppresses glioblastoma tumor growth by AKT-mediated inhibition of GLI1. Oncotarget Oncotarget. 2017 May 16;8(20):32960-32976. doi: 10.18632/oncotarget.16515. PMID:28380428.
- Ranjan A, Wright SE, and Srivastava SK (2017). Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth. Oncotarget 2017 Apr 26. doi: 10.18632/oncotarget.17425. [Epub ahead of print] PMID: 28512255.
- Ranjan A, German N, Mikelis C, Srivenugopal K, Srivastava SK. (June 2017) Penfloridol induces endoplasmic reticulum stress leading to autophagy in pancreatic cancer. Tumor Biology June 2017, 39:6, (1-7), doi:10.1177/1010428317705517
- Kwon HY, Kim JH, Kim B, Srivastava SK, Kim SH (2017). Regulation of SIRT1/AMPK axis is critically involved in gallotannin-induced senescence and impaired autophagy leading to cell death in hepatocellular carcinoma cells. Arch Toxicol. 2017 Jul 4. doi: 10.1007/s00204-017-2021-y. [Epub ahead of print] PMID: 28676953
Patents
- #PCT/US 2018: 60763 - Composition and methods for treating cancer. (Sanjay K. Srivastava)
- PCT/US2016 #036002 - Inhibitors of Mcl-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors (Sanjay K. Srivastava)
- #62/172,327 - Inhibitors of Mcl-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors (Sanjay K. Srivastava)
- # 62/189,377 - Formulations of piperlongumine for oral and topical application for prevention and treatment of melanoma (Sanjay K. Srivastava)
- #62026970 - Overcoming Chemotherapeutic Agent Resistance in Cancer by Inhibiting Mcl-1 (Sanjay K. Srivastava)
- WO2014210411 A1 - Histone deacetylase inhibitors and methods of use (Sanjay K. Srivastava)
- #61973672 - Overcoming vemurafinib resistance in metastatic cancers (Sanjay K. Srivastava)
- #62026970 - Overcoming chemotherapeutic agent resistance in cancer by inhibiting Mcl-1 (Sanjay K. Srivastava)
- #61840751 - Histone deacetylase inhibitors and methods of use (Sanjay K. Srivastava)
- WO2013/074820 - Immunogenic tumor associated stromal cell antigen peptides and methods of their use. (WJ Storkus, A. Bose, JL Taylor, X Zhao, DB Lowe)